Biomarkers: diagnostic highlights and surrogate end points

By Levenson Victor V  

Pharmacogenomics, Vol. 5, Iss. 5, 2004-07 ,pp. : 459-461

Future Medicine

Access to resources Recommend Favorite

Estimating the Cost Effectiveness of Ramipril used for Specific Clinical Indications: Comparing the Outcomes in Four Clinical Trials with a Common Economic Model

By Grover Steven A.   Coupal Louis   Lowensteyn Ilka  

American Journal of Cardiovascular Drugs, Vol. 7, Iss. 6, 2007-01 ,pp. : 441-448

Adis International

Access to resources Recommend Favorite

Preliminary patient-reported outcomes analysis of 3-dimensional radiation therapy versus intensity-modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group (RTOG) 0126 prostate cancer trial

By  

Cancer, Vol. 121, Iss. 14, 2015-07 ,pp. : 2422-2430

Blackwell Publishing

Access to resources Recommend Favorite

The Impact of Biomarkers and Surrogate End Points on Regulatory Approval of New Drugs

By  

Heart Drug, Vol. 2, Iss. 5, 2003-01 ,pp. : 235-245

Karger

Access to resources Recommend Favorite

The State of Patient-Reported Outcomes in Atrial Fibrillation: A Review of Current Measures

By Coyne Karin  

PharmacoEconomics, Vol. 23, Iss. 7, 2005-01 ,pp. : 687-708

Adis International

Access to resources Recommend Favorite